Abbott Laboratories (ABT) Earnings Call Transcripts

Abbott Laboratories's Latest Earnings Call - Q2 FY2026

In the second quarter of fiscal year 2026, Abbott Laboratories (ABT:US) reported a revenue increase of 4.8% year-over-year, reaching $10.5 billion, and adjusted earnings per share (EPS) of $1.31, exceeding both the midpoint of guidance and consensus estimates. Management reaffirmed full-year guidance for comparable sales growth of 6.5% to 7.5% and raised EPS guidance to a range of $5.45 to $5.60. The results indicate strong momentum across several business segments, particularly in diagnostics and nutrition, which could positively influence stock performance moving forward.

Reported metrics

Guidance from management

Abbott maintained its full-year sales growth guidance of 6.5% to 7.5% and raised its EPS guidance to $5.45 to $5.60, reflecting confidence in the second half of the year.

What management said

You can criticize, Larry. That's fine. We are -- this is a good business, and it's doing very well. I know it gets a lot of attention for -- because of us and the competitor. But it's a good business. There's a lot of opportunity here. I'm just trying to provide context of the opportunities and how this will accelerate given reimbursement expansions.

Thank you all for your questions. This now concludes Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central Time today on our website, abbott.com. Thank you for joining us today.

What analysts pressed on

Analysts raised concerns about potential deceleration in procedure volumes, particularly in the U.S. Ford addressed these concerns by stating, "We're not seeing that... our data is not showing that," indicating stable demand across their segments.

Main topics on the call

• Revenue Growth Acceleration — Abbott's revenue grew by 4.8% in Q2 2026, an acceleration from previous quarters. CEO Robert Ford stated, "Our growth rate stepped up to mid-single digits from where it was in the last 2 quarters of low single digits."
• Guidance Revision — Management raised EPS guidance to $5.45 to $5.60, reflecting confidence in ongoing performance. Ford noted, "We have momentum building across the portfolio and clear line of sight to the key drivers of sales growth accel...
• Strong Performance in Diagnostics — The diagnostics segment saw a 7.5% growth in the U.S. core laboratory business, indicating strong demand. Ford emphasized, "Our U.S. cardio business is performing better than it's ever been."
• Nutrition Segment Recovery — Nutrition sales increased sequentially by $125 million, driven by pediatric and adult nutrition. Ford highlighted, "In U.S. pediatric, we exited the quarter with the full benefit of recent WIC contract wins reflected in ...

Read the full Abbott Laboratories transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 32 Abbott Laboratories earnings call transcripts on record, spanning January 14, 2020 to July 16, 2026. Based on this history, Abbott Laboratories reports quarterly. The most recent call on file is dated July 16, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ABT

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

32

First call

January 14, 2020

Most recent

July 16, 2026

Reporting cadence

quarterly